DuPont Merck & Scios Sign Alzheimer's Deal

27 November 1997

DuPont Merck Pharmaceutical and Scios Inc have announced the signing ofan agreement establishing a research collaboration into Alzheimer's disease, with the initial focus being on using Scios' high-throughput screening systems to identify useful DuPont Merck compounds.

Under the terms of the agreement, DuPont Merck has agreed to purchase $3 million of Scios common stock, and will make milestone and royalty payments. Additional financial terms of the deal were not disclosed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight